| Bioactivity | TAK-603 is a potent and orally active antirheumatic agent. TAK-603 inhibits Thl-type cytokine production. TAK-603 has the potential for the research of adjuvant arthritis[1][2]. |
| Invitro | TAK-603 (0, 1, 10 µM; 48 h) 抑制同种异体反应性和 OVA 反应性 BALB/c 小鼠 T 细胞系中的 IFN-γ 的产生，但对 IL-4 产生几乎没有影响 [2]. |
| In Vivo | TAK-603 (6.25 mg/kg；口服；每天) 减少关节炎病变和脾脏中 Thl-型细胞因子的产生[2]。 Animal Model: |
| Name | TAK-603 |
| CAS | 158146-85-1 |
| Formula | C25H26N4O6 |
| Molar Mass | 478.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mizuno M, et al. Syntheses of metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603). Tetrahedron, 2006, 62(37), 8707–8714. [2]. Ohta Y, et al. TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis. Immunology. 1997 Sep;92(1):75-83. |